Analysts Lower Alnylam Targets to $360 and $450 Citing Headwinds
Morgan Stanley cut Alnylam’s price target to $360 from $408, keeping an Equal Weight rating; RBC Capital lowered its target to $450 from $465 with Outperform rating, citing near-term headwinds. Analysts flagged an 80% undiagnosed rate among 300,000 TTR-CM patients and Alnylam’s pipeline expansion into Huntington’s disease, obesity and HHT.
1. Analyst Price Target Revisions
Morgan Stanley cut Alnylam’s price target to $360 from $408 while maintaining an Equal Weight rating; RBC Capital lowered its target to $450 from $465 and kept an Outperform rating.
2. Analyst Outlook on Near-Term Performance
Both firms cited near-term headwinds despite strong commercial execution in 2025, noting the company’s preannounced fourth-quarter revenue and reaffirmed 2026 transthyretin amyloidosis sales guidance as signals of launch confidence.
3. Market Opportunity and Pipeline Growth
Analysts highlighted that 80% of an estimated 300,000 global TTR-CM patients remain undiagnosed, and pointed to Alnylam’s expansion into Huntington’s disease, obesity and hereditary hemorrhagic telangiectasia as drivers for future growth.